Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
ACTG A5275 was a prospective, double-blind, randomized, placebo-controlled cross-over design
pilot study evaluating the effect of atorvastatin on biomarkers of inflammation,
coagulopathy, angiogenesis, and T-lymphocyte activation in HIV-1 infected individuals with
suppressed HIV-1 RNA on stable protease inhibitor based antiretroviral therapy with fasting
LDL cholesterol < 130 mg/dL.
Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for treating high
cholesterol. Atorvastatin has also been able to lower the level of inflammation blood tests
in certain other diseases but has not been studied for this purpose in people who have HIV.
The main goal of this experimental study is to see how taking atorvastatin affects
inflammation blood tests in people infected with HIV who do not need to take medicine for
high cholesterol. In addition to observing the effects of atorvastatin on the level of
inflammation measured in the blood, this study evaluated if atorvastatin is safe for people
with HIV who are also taking medication for HIV.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) Pfizer